Lee, Hans C.
Raje, Noopur S.
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Upreti, Vijay V.
Wang, Jin
Avilion, Ariel A.
Hu, Xuguang
Rasmussen, Erik
Ngarmchamnanrith, Gataree
Fujii, Hisaki
Spencer, Andrew
Funding for this research was provided by:
Amgen
Article History
Received: 19 December 2019
Accepted: 6 April 2020
First Online: 21 April 2020
Compliance with ethical standards
:
: HCL: research support and consultant/advisor (Amgen, Celgene, Janssen, and Takeda), consultant/advisor (GlaxoSmithKline and Sanofi), and research support (Daiichi Sankyo). NSR: consultant (Amgen Inc., Takeda, Celgene, Bristol-Myers Squibb, Janssen, Bluebird, and Karyopharm). OL: research funding (National Institutes of Health, U.S. Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tide Foundation, Amgen Inc., Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm); honoraria and advisory boards (Adaptive, Amgen Inc., Binding Site, Bristol-Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer); and Independent Data Monitoring Committees (Takeda, Merck, and Janssen). VVU, JW, AAA, XH, ER, GN, and HF: employment by and stock ownership in Amgen Inc. AS: consultant (Celgene, Janssen, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, HaemaLogiX, and Sanofi); speaker’s bureau (Celgene, Janssen, and Takeda); grant/Research Support (Celgene, Janssen, Amgen Inc., Takeda, Servier, HaemaLogiX); honoraria (Celgene, Janssen, Amgen Inc., Takeda, Secura Bio, Specialised Therapeutics Australia, AbbVie, Servier, HaemaLogiX, and Sanofi).